Mercer Global Advisors Inc Seagen Inc. Transaction History

Mercer Global Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $1,723 - $1,945	9 Added 0.28%	3,273 $694,000
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $126,094 - $138,600	672 Added 25.93%	3,264 $628,000
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $20,924 - $33,305	-164 Reduced 5.95%	2,592 $524,000
Q4 2022 Feb 08, 2023	SELL	$117.37 - $139.17 $23,943 - $28,390	-204 Reduced 6.89%	2,756 $354,000
Q3 2022 Nov 15, 2022	SELL	$135.27 - $180.11 $133,782 - $178,128	-989 Reduced 25.04%	2,960 $405,000
Q2 2022 Aug 10, 2022	BUY	$108.81 - $179.33 $89,441 - $147,409	822 Added 26.29%	3,949 $699,000
Q1 2022 May 10, 2022	SELL	$119.61 - $157.85 $10,406 - $13,732	-87 Reduced 2.71%	3,127 $450,000
Q4 2021 Feb 04, 2022	SELL	$142.57 - $190.86 $26,803 - $35,881	-188 Reduced 5.53%	3,214 $497,000
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $220,939 - $263,390	1,551 Added 83.79%	3,402 $578,000
Q2 2021 Aug 10, 2021	SELL	$135.08 - $161.1 $1.09 Million - $1.3 Million	-8,051 Reduced 81.31%	1,851 $292,000
Q1 2021 May 11, 2021	BUY	$137.51 - $190.8 $1.1 Million - $1.53 Million	7,997 Added 419.79%	9,902 $1.38 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $313,620 - $403,726	1,905 New	1,905 $334,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.